<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163227">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02038296</url>
  </required_header>
  <id_info>
    <org_study_id>TAE001</org_study_id>
    <nct_id>NCT02038296</nct_id>
  </id_info>
  <brief_title>Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate local tumor control and survival rate after repeated transarterial
      chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC)
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1-2 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 received single-drug (doxorubicin)transarterial chemoembolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed HCC with unresectable disease without
             extrahepatic metastases;

          -  HCC with no previous treatment;

          -  age between 18 and 75 years;

          -  Life expectancy of at least 8 weeks;

          -  main tumor size greater than 5 cm;

          -  adequate hematologic function (platelet count: &gt;60 × 109 platelets/L; hemoglobin:
             &gt;90g/L; and prothrombin time: &lt;3 seconds above control);

          -  adequate renal function (serum creatinine: ≤1.5 × upper limit of normal);

          -  Child-Pugh classification A or B grade;

          -  Barcelona Clinic Liver Cancer (BCLC) stage B or C;

          -  Eastern Co-operative Group performance status of zero or one.

        Exclusion Criteria:

          -  a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced
             than the nontumorous liver parenchyma on arterial phase computed tomography scans);

          -  diffuse-type HCC;

          -  evidence of hepatic decompensation including esophageal or gastric variceal bleeding
             or hepatic encephalopathy;

          -  severe underlying cardiac or renal diseases;

          -  color Doppler ultrasonography showing portal vein tumor thrombosis with complete main
             portal vein obstruction without cavernous transformation; or    obstructive jaundice.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Interventional Radiology; Cancer Center; Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Transarterial chemoembolization</keyword>
  <keyword>Gemcitabine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
